Menopause series
Menopause Weight Gain and Mounjaro: Why It Happens and What Helps
The scales often start creeping in the years around the last period, and it is not imagination or a failure of willpower. Long-term research shows the rate of fat gain roughly doubles at the start of the menopause transition while muscle quietly declines, and the new fat prefers the waist. This guide explains what is actually changing, why the methods that used to work stop working, and what Mounjaro can and cannot realistically do about it.
Key facts
- In the long-running SWAN study, which tracked over 1,200 women with body scans for 18 years, the rate of fat gain doubled at the start of the menopause transition and lean muscle began to decline, with both changes continuing until about two years after the final period.
- Total weight often does not accelerate, because fat gained and muscle lost roughly cancel out on the scales. That is why waistbands change faster than the number you weigh.
- Falling oestrogen shifts fat storage towards the abdomen, including the deeper visceral fat linked to type 2 diabetes and heart disease.
- Mounjaro has been licensed in the UK for weight management since 2023, for adults with a BMI of 30 or more, or 27 or more with a weight-related condition. Menopause itself is not a licensing criterion, but around two thirds of participants in the main trial were women.
- Early research published in January 2026 found postmenopausal women taking HRT lost around 35% more weight on tirzepatide than similar women not on HRT, though this needs confirming in larger trials.
What actually changes at menopause
For a long time nobody could say whether midlife weight gain was menopause or simply ageing. The Study of Women’s Health Across the Nation, known as SWAN, settled much of the argument by scanning the same women with DXA body composition scans for 18 years, from roughly nine years before their final period to ten years after. The pattern it found is worth knowing, because it explains what so many women describe.
| Measure | What the research found |
|---|---|
| Fat mass | The rate of gain roughly doubles at the start of the menopause transition and keeps climbing until about two years after the final period, then levels off. |
| Muscle (lean mass) | Begins to decline around two years before the final period, after rising slowly through the early 40s. |
| Total weight | Does not suddenly accelerate. Fat gained and muscle lost roughly balance, so the scales understate what is happening underneath. |
| Where fat sits | Storage shifts towards the abdomen, including visceral fat around the organs, which carries more health risk than fat elsewhere. |
The average final period arrives at around 51 to 52, with the transition usually starting in the mid 40s, so these changes can be well under way before anyone connects them to menopause. Hot flushes announce themselves; body composition does not.
Why losing it feels harder than before
Several things stack up at once. Losing muscle lowers the number of calories your body burns at rest, so the portions that maintained your weight at 40 quietly become a surplus at 50. Night sweats and broken sleep push hunger hormones in the wrong direction the next day, making cravings sharper and snacking easier. Joint aches, low mood and sheer exhaustion tend to reduce everyday movement without you deciding anything. None of these are character flaws; they are physiology, and they respond to the right tools.
It is also why crash dieting backfires particularly badly at this age. Aggressive calorie cuts without protein and strength work strip more of the muscle you are already losing, which lowers your calorie burn further and makes regain more likely.
Where Mounjaro fits
Mounjaro (tirzepatide) is a weekly injection that mimics two gut hormones, GLP-1 and GIP. Together they quieten appetite, reduce the constant background pull towards food that many describe as food noise, and slow how quickly the stomach empties so meals satisfy for longer. It directly counters the sharpened hunger and cravings that menopause brings, which is why so many midlife women get on well with it.
It has been licensed in the UK for weight management since 2023, prescribed alongside diet and activity for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure. Our BMI requirements guide covers eligibility in detail. Menopause itself is not a criterion either way: it neither qualifies you nor excludes you.
The trial evidence includes women in their 40s, 50s and beyond. In SURMOUNT-1, the main licensing trial, around two thirds of the 2,539 participants were women, and average weight loss reached about 15% of body weight on the 5 mg dose and about 21% on 15 mg over 72 weeks. Those are averages built over a year and a half, not a first-month promise, and roughly one person in ten still lost under 5%. Menopause does not switch the medicine off, but it does not suspend the usual honesty about averages either.
Mounjaro and HRT together
Plenty of women arrive at Mounjaro already using HRT, and the two are commonly taken together. There are two things worth knowing. First, a Mayo Clinic study published in The Lancet Obstetrics, Gynaecology and Women’s Health in January 2026 found postmenopausal women on hormone therapy lost around 35% more weight on tirzepatide than similar women not using it, echoing an earlier finding with semaglutide. It was a retrospective study of 120 women, so it suggests rather than proves. Second, because Mounjaro slows stomach emptying, the tablet forms of HRT need a proper conversation with your prescriber, while patches, gels and sprays are unaffected.
Both points, including exactly which HRT types are affected and who to tell, are covered properly in our dedicated guide to taking Mounjaro alongside HRT.
Protect muscle and bone while you lose
Menopause is already taking lean mass, and a portion of any rapid weight loss is lean mass too, so midlife women have more reason than anyone to lose deliberately rather than dramatically. That means protein at every meal, resistance work two or three times a week even if it is bodyweight or bands at home, and a losing rate of roughly 0.5 to 1 kg a week after the starting doses rather than chasing bigger numbers. The same habits protect bone, which matters because the body composition shifts of the transition are linked to bone density and fracture risk later.
Eating enough protein on a suppressed appetite takes planning, and our nutrition guide covers how to do it when you are simply not hungry. The free Augo app can track measurements and progress photos alongside weight, which tells a fairer story than the scales at an age when composition changes more than weight.
NHS or private
Mounjaro is available on the NHS for weight management, but through a phased rollout that currently reaches only people with the highest clinical need, so most menopausal women using it today buy privately through regulated online pharmacies. Eligibility for the NHS route is covered in our NHS guide, and what each route costs at midlife, including HRT prescription costs, is the whole subject of our guide to the cost of menopause weight loss.
Common questions
Does menopause cause weight gain?
It changes body composition more than it changes the scales. Research following women through the transition found the rate of fat gain doubles and muscle declines from about two years before the final period, with fat shifting towards the waist. Combined with ageing and disrupted sleep, that makes gradual weight gain very common, though not inevitable.
Does Mounjaro work for menopause weight gain?
For eligible women, yes. The licensing trials included women of menopausal age, and the medicine targets exactly the appetite and craving pressure that menopause sharpens. Expect the same realistic pattern as anyone else: a quiet first month on the starting dose, then steadier loss as doses build.
Is Mounjaro licensed for menopause?
No. It is licensed for weight management based on BMI criteria, and for type 2 diabetes. Menopause is not an indication in itself, so eligibility depends on your BMI and any weight-related conditions, not on your menopausal status.
Will Mounjaro reduce belly fat after menopause?
No medicine can target one area, but meaningful weight loss reliably reduces visceral fat, the deeper abdominal fat that menopause encourages. Many women find waist measurements improve noticeably, which matters more for health than the number on the scales.
Do I need to take HRT for Mounjaro to work?
No. Mounjaro works with or without HRT. Early research suggests women on hormone therapy may lose more, but HRT is a decision about menopause symptoms to make with your own prescriber, not a weight loss accessory. Our Mounjaro and HRT guide covers the evidence.
How much weight do menopausal women lose on Mounjaro?
The trials averaged about 15% of body weight on 5 mg and 21% on 15 mg after 72 weeks, and most participants were women. Individuals vary widely around those averages, and they took a year and a half of continuous treatment to build.
Can I manage menopause weight gain without medication?
Many women can. Resistance training, protein-led meals, decent sleep and steady activity address the actual mechanisms of midlife gain. Medicines are an option when BMI criteria are met and lifestyle changes alone have not been enough, not a first resort.
Sources
- Greendale GA et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight, 2019.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Castaneda R et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women. The Lancet Obstetrics, Gynaecology and Women’s Health, 2026.
- NHS. Menopause: overview. NHS.uk.
- Medicines and Healthcare products Regulatory Agency. MHRA authorises tirzepatide for weight management and weight loss. GOV.UK, 2023.
Monj is an independent price information service operated by Medstack Ltd. It does not sell, prescribe or supply medicines and does not give medical advice. Whether Mounjaro or HRT is right for you is a decision for you and your prescriber. Report suspected side effects through the MHRA Yellow Card scheme.
